On August 24, ALI HEALTH fell 3.07% in regular trading, trading at HKD 3.155/share, with turnover of HKD 58.10 million.

On the news front, parent company Alibaba announced its first new share placement since its Hong Kong listing, totaling HKD 80 billion at a discount of 3.6% to 9%, with proceeds earmarked entirely for full-stack AI capabilities and infrastructure development. The dilution concerns triggered an 8.57% drop in Alibaba US shares and a 10.16% decline in BABA-W in Hong Kong, dragging affiliated names including ALI HEALTH lower in sympathy.

The placement represents approximately 4% of Alibaba's market capitalization and is the largest single fundraising in recent years. The scale broadly matches the market's prior estimates of Alibaba's potential funding gap over the next three years. Notably, Alibaba had previously reduced its share capital by approximately 15% through buybacks and cancellations over recent years. Within the Internet and Direct Marketing Retail sector, BABA-W fell 10.0%, JD HEALTH fell 3.21%, MEITUAN-W fell 2.94%, JD-SW fell 2.6%, and PA GOODDOCTOR fell 1.56%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)